MedWatch

Novo Seeds invests in Dutch biotech firm with NASH focus again

For the third time, Novo Holding's venture arm Novo Seeds has invested in biotech company Northsea Therapeutics. This will allow the latter to start a phase III study of a candidate within NASH and continue phase I and II studies of other candidates.

Søren Møller, Leading Partner at Novo Seeds | Photo: Novo Holdings / PR

Novo Seeds, the department of Novo Holdings which works with early investments, has expressed confidence in Northsea Therapeutics by investing in it for the third time.

Northsea Therapeutics is a biotech firm based in the Netherlands which is developing treatments for fatty liver disease NASH and other metabolic, inflammatory and fibrosis-related diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs